Company profile
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MUPADOLIMAB | phase3 | — | 3 | completed, terminated |
| Soquelitinib | phase1 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03952078 | phase1 | active_not_recruiting | 2019-05-03 | 2026-04-30 | Corvus Pharmaceuticals, Inc. | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma |
| NCT03454451 | phase1 | completed | 2018-04-25 | 2022-12-28 | Corvus Pharmaceuticals, Inc. | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers |
| NCT04734873 | phase3 | terminated | 2021-02-25 | 2021-08-18 | Corvus Pharmaceuticals, Inc. | CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients |
| NCT02655822 | phase1 | completed | 2016-01-01 | 2021-06-01 | Corvus Pharmaceuticals, Inc. | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers |
| NCT06345404 | phase1 | completed | 2024-04-16 | 2026-01-28 | Corvus Pharmaceuticals, Inc. | Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD |
FDA applications (0)
No records yet.